RxDoctor Payments Data

Allan Memoracion, NP

Adult Health · Bay Shore, NYNPI 1770038390

Payments from drug & device makers

$1,864in general payments, 2019–2025

Across 48 payments — averaging $38.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$563
  • Boston Scientific$270
  • Heartflow, Inc.$253
  • Abbott$177
  • Merck$125
  • Baxter Healthcare$103
  • plus $374 from 9 others

What the payments were for

  • Food & beverage$1,76094%
  • Education$1046%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,864 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$30,627
Medicare patients
215
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban399$563,262
VyndamaxTafamidis17$365,584
EntrestoSacubitril/Valsartan170$237,201
AdempasRiociguat12$204,711
FarxigaDapagliflozin Propanediol148$149,086
XareltoRivaroxaban83$111,344
JardianceEmpagliflozin55$79,478
Repatha SureclickEvolocumab113$74,246
OzempicSemaglutide29$36,993
MultaqDronedarone Hcl27$35,035
MounjaroTirzepatide18$28,059
Repatha SyringeEvolocumab33$23,398
Praluent PenAlirocumab14$14,580
Metoprolol Succinate657$10,376
Ranolazine ErRanolazine54$7,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$35$928,847416 claims
NovartisEntresto$84$237,201170 claims
AstraZenecaFarxiga$14$149,086148 claims
Johnson & JohnsonXarelto$19$111,34483 claims
Novo NordiskOzempic$42$36,99329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →